Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature

Poly-ADP-ribose-polymerase inhibitor (PARPi) treatment is indicated for advanced-stage ovarian tumors with BRCA1/2 deficiency. The “BRCAness” status is thought to be attributed to a tumor phenotype associated with a specific epigenomic DNA methylation profile. Here, we examined the diagnostic impact...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Hum Genet
Autors principals: Aref-Eshghi, Erfan, McGee, Jacob D., Pedro, Victor P., Kerkhof, Jennifer, Stuart, Alan, Ainsworth, Peter J., Lin, Hanxin, Volodarsky, Michael, McLachlin, Catherine Meg, Sadikovic, Bekim
Format: Artigo
Idioma:Inglês
Publicat: Springer Singapore 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7449880/
https://ncbi.nlm.nih.gov/pubmed/32483276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s10038-020-0780-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars